Pharma Industry Under Antitrust Scrutiny

Law360, New York (January 13, 2010, 10:57 AM EST) -- Competition authorities continue to examine various aspects of the pharmaceutical industry. Most recently, the European Commission conducted surprise inspections of certain pharmaceutical companies, seeking evidence of anti-competitive conduct.

One issue of concern is the impact on competition of "pay-for-delay" or "reverse payment" patent settlement agreements, whereby branded pharmaceutical manufacturers make payments to generic manufacturers in exchange for delaying their entry.

Although this issue has yet to be a specific focus of concern in Canada, recent amendments to the Competition Act (to come into force in March...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.